Q-omics provides the consensus-scored PCED1CP profile across patient tissues and cancer cell-line models. PCED1CP expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PCED1CP is differentially expressed in 4, with the highest sampling consensus in LUSC. Additionally, PCED1CP RNA expression shows 10,841 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, LUSC, and TGCT as cancer lineages where PCED1CP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCED1CP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCED1CP survival associations across molecular data types. PCED1CP RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCED1CP RNA expression–survival associations across cancer types. High PCED1CP expression shows unfavorable associations in ACC, KICH, UCS, KIRC and LUAD, but favorable associations in HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PCED1CP RNA expression.
This table summarizes PCED1CP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for PCED1CP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCED1CP shows lower tumor expression in KIRC and higher tumor expression in LUSC, THCA and LUAD. The LUSC box plot shows higher PCED1CP RNA expression in tumor versus normal tissue (log2 FC = +0.036, t-test p < 0.001).
This table shows molecular features associated with PCED1CP in patient tissues and cancer cell lines. In patient samples, PCED1CP shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
